Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast

Authors

Utsav Joshi, Rochester Regional HealthFollow
Pravash Budhathoki, Department of Internal Medicine, Bronxcare Health System, Bronx, NY, 10457, USA.
Suman Gaire, Department of Internal Medicine, Mount Sinai Hospital Chicago, Chicago, IL, 60608, USA.
Sumeet K. Yadav, Department of Hospital Internal Medicine, Mayo Clinic, Mankato, MN, 56001, USA.
Anish Shah, Department of Internal Medicine, Bronxcare Health System, Bronx, NY, 10457, USA.
Anurag Adhikari, Department of Internal Medicine, Jacobi Medical Center, New York, NY, 10461, USA.
Grace Choong, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Rima Couzi, Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, 21231, USA.
Karthik V. Giridhar, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Roberto A. Leon-Ferre, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Judy C. Boughey, Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Tina J. Hieken, Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, 55905, USA.
Robert Mutter, Department of Radiation Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Kathryn J. Ruddy, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Tufia C. Haddad, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Matthew P. Goetz, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Fergus J. Couch, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Siddhartha Yadav, Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.

Department

Internal Medicine

Document Type

Article

Publication Title

Breast Cancer Research and Treatment

Abstract

PURPOSE: Triple-negative invasive lobular carcinoma (TN-ILC) of breast cancer is a rare disease and the clinical outcomes and prognostic factors are not well-defined.

METHODS: Women with stage I-III TN-ILC or triple-negative invasive ductal carcinoma (TN-IDC) of the breast undergoing mastectomy or breast-conserving surgery between 2010 and 2018 in the National Cancer Database were included. Kaplan-Meier curves and multivariate Cox proportional hazard regression were used to compare overall survival (OS) and evaluate prognostic factors. Multivariate logistic regression was performed to analyze the factors associated with pathological response to neoadjuvant chemotherapy.

RESULTS: The median age at diagnosis for women with TN-ILC was 67 years compared to 58 years in TN-IDC (p < 0.001). There was no significant difference in the OS between TN-ILC and TN-IDC in multivariate analysis (HR 0.96, p = 0.44). Black race and higher TNM stage were associated with worse OS, whereas receipt of chemotherapy or radiation was associated with better OS in TN-ILC. Among women with TN-ILC receiving neoadjuvant chemotherapy, the 5-year OS was 77.3% in women with a complete pathological response (pCR) compared to 39.8% in women without any response. The odds of achieving pCR following neoadjuvant chemotherapy were significantly lower in women with TN-ILC compared to TN-IDC (OR 0.53, p < 0.001).

CONCLUSION: Women with TN-ILC are older at diagnosis but have similar OS compared to TN-IDC after adjusting for tumor and demographic characteristics. Administration of chemotherapy was associated with improved OS in TN-ILC, but women with TN-ILC were less likely to achieve complete response to neoadjuvant therapy compared to TN-IDC.

First Page

217

Last Page

224

DOI

10.1007/s10549-023-06959-3

Volume

200

Issue

2

Publication Date

7-1-2023

Medical Subject Headings

Female; Humans; Aged; Breast Neoplasms (pathology); Carcinoma, Lobular (pathology); Prognosis; Carcinoma, Ductal, Breast (pathology); Mastectomy

PubMed ID

37210429

Share

COinS